Personalized risk prediction for event-free ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
Auteur(s) :
Maurer Matthew, J [Auteur]
Jais, Jean-Philippe [Auteur]
Ghesquieres, Herve [Auteur]
Witzig Thomas, E [Auteur]
Hong, Fangxin [Auteur]
Haioun, Corinne [Auteur]
Thompson Carrie, A [Auteur]
Thieblemont, Catherine [Auteur]
Micallef Ivana, N [Auteur]
Porrata Luis, F [Auteur]
Ribrag, Vincent [Auteur]
Nowakowski Gregorz, S [Auteur]
Casasnovas, Olivier [Auteur]
Bologna, Serge [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Morrison Vicki, A [Auteur]
Peterson Bruce, A [Auteur]
Macon William, R [Auteur]
Copie-Bergman, Christiane [Auteur]
Feldman Andrew, L [Auteur]
Syrbu Sergei, I [Auteur]
Kurtin Paul, J [Auteur]
Gascoyne Randy, D [Auteur]
Li, Hailun [Auteur]
Allmer, Cristine [Auteur]
Kahl Brad, S [Auteur]
Ansell, Stephen [Auteur]
Slager Susan, L [Auteur]
Link Brian, K [Auteur]
Salles, Gilles [Auteur]
Habermann Thomas, M [Auteur]
Tilly, Herve [Auteur]
Cerhan James, R [Auteur]
Jais, Jean-Philippe [Auteur]
Ghesquieres, Herve [Auteur]
Witzig Thomas, E [Auteur]
Hong, Fangxin [Auteur]
Haioun, Corinne [Auteur]
Thompson Carrie, A [Auteur]
Thieblemont, Catherine [Auteur]
Micallef Ivana, N [Auteur]
Porrata Luis, F [Auteur]
Ribrag, Vincent [Auteur]
Nowakowski Gregorz, S [Auteur]
Casasnovas, Olivier [Auteur]
Bologna, Serge [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Morrison Vicki, A [Auteur]
Peterson Bruce, A [Auteur]
Macon William, R [Auteur]
Copie-Bergman, Christiane [Auteur]
Feldman Andrew, L [Auteur]
Syrbu Sergei, I [Auteur]
Kurtin Paul, J [Auteur]
Gascoyne Randy, D [Auteur]
Li, Hailun [Auteur]
Allmer, Cristine [Auteur]
Kahl Brad, S [Auteur]
Ansell, Stephen [Auteur]
Slager Susan, L [Auteur]
Link Brian, K [Auteur]
Salles, Gilles [Auteur]
Habermann Thomas, M [Auteur]
Tilly, Herve [Auteur]
Cerhan James, R [Auteur]
Titre de la revue :
American journal of hematology
Nom court de la revue :
Am. J. Hematol.
Numéro :
91
Pagination :
179-184
Date de publication :
2016
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
We recently defined event-free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent ...
Lire la suite >We recently defined event-free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline-based immunochemotherapy. A multivariable model containing age, Ann Arbor stage, normalized serum LDH, ALC, ECOG performance status, bulky disease, and sex was identified. The model was then applied to an independent validation dataset of 1,177 DLBCL patients. The IPI24 score estimates the probability of failing to achieve the EFS24 endpoint for an individual patient. The IPI24 model showed superior discriminatory ability (c-statistic = 0.671) in the validation dataset compared to the IPI (c-statistic = 0.649) or the NCCN-IPI (c-statistic = 0.657). After recalibration of the model on the combined dataset, the median predicted probability of failing to achieve EFS24 was 36% (range, 12-88%), and the IPI24 showed an EFS24 gradient in all IPI groups. The IPI24 also identified a significant percentage of patients with high risk disease, with over 20% of patients having a 50% or higher risk of failing to achieve EFS24. The IPI24 provides an individual patient level probability of achieving the clinically relevant EFS24 endpoint. It can be used via electronic apps.Lire moins >
Lire la suite >We recently defined event-free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline-based immunochemotherapy. A multivariable model containing age, Ann Arbor stage, normalized serum LDH, ALC, ECOG performance status, bulky disease, and sex was identified. The model was then applied to an independent validation dataset of 1,177 DLBCL patients. The IPI24 score estimates the probability of failing to achieve the EFS24 endpoint for an individual patient. The IPI24 model showed superior discriminatory ability (c-statistic = 0.671) in the validation dataset compared to the IPI (c-statistic = 0.649) or the NCCN-IPI (c-statistic = 0.657). After recalibration of the model on the combined dataset, the median predicted probability of failing to achieve EFS24 was 36% (range, 12-88%), and the IPI24 showed an EFS24 gradient in all IPI groups. The IPI24 also identified a significant percentage of patients with high risk disease, with over 20% of patients having a 50% or higher risk of failing to achieve EFS24. The IPI24 provides an individual patient level probability of achieving the clinically relevant EFS24 endpoint. It can be used via electronic apps.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Équipe(s) de recherche :
Innovation/évaluation des médicaments injectables
Date de dépôt :
2019-02-26T17:07:32Z